Apellis Pharmaceuticals’ stock offering closes $50M higher than expected

//Apellis Pharmaceuticals’ stock offering closes $50M higher than expected

Apellis Pharmaceuticals’ stock offering closes $50M higher than expected

Boston-based Apellis Pharmaceuticals Inc. brought in an additional $53 million through its recently announced public common stock offering. The late-stage biopharmaceutical company announced Jan. 10 that it was issuing 9.5 million shares that were estimated to produce gross proceeds of $351.5 million. The offering also included the option for financial firms involved with the stock offering to acquire an additional 1.4 million shares at the offering's share price of $37. Those firms fully exercised…

Article by [author-name] (c) Health Care News - Health Care News Headlines | Bizjournals.com - Read full story here.

By | 2020-01-13T21:57:34+00:00 January 13th, 2020|Healthcare|

About the Author: